Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Panelists Urge Exclusion of LLPs from Copay Increase If Generic Access Is Difficult
November 30, 2023
- Pharma in Dogged Fight against Expansion of CEA Price Tweaks, Flags “Camel’s Nose”
November 29, 2023
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023
- Syphilis Cases in Japan Mark Record High for 3rd Consecutive Year
November 28, 2023
- LDP League Leader Vows to Push Self-Medication to Sustain Healthcare System
November 28, 2023
- LDP League on Medical Patches Cautions against Hasty Debate on LLP Copay
November 28, 2023
- Medipharma Altered Data in at Least 7 Clinical Trials: MHLW
November 28, 2023
- Meiji’s mRNA Vaccine, Pfizer’s RSV Vaccine Now in Line for Approval
November 28, 2023
- Chuikyo Supports Adding More Dosage Forms to “Minimum Price” Category, Urges Improvements in Distribution Practices
November 27, 2023
- HCPs, Payers Spat over Extension of Add-On Fee Premiums Related to Drug Supply Issues
November 27, 2023
- As Leqembi Listing Approaches, Chuikyo OKs Coverage for PET Device and Diagnostics
November 27, 2023
- Ultragenyx’s Evinacumab, Alexion’s Danicopan Up for Japan Panel Review on Dec. 8
November 27, 2023
- Pool Fever Reaches Alert Level in Japan for 1st Time in Decade: NIID
November 27, 2023
- Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
- Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
- Japan Grants Orphan Tags to MSD’s MK-3475A, 3 More Drugs
November 27, 2023
- COVID Vaccines to Join NIP for Ages 65-Plus from April, with Copay Required
November 24, 2023
- No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo
November 24, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…